Spero
spero.ai
Actively hiring
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Spero is a medical technology company headquartered in Moscow, Russia, that was established in 2019. The organization specializes in the development of the SPERO-screen, a diagnostic system that utilizes hormonal blood test results and patient data to predict fertility windows through proprietary mathematical algorithms. It operates across major Russian cities through partnerships with clinical laboratories and offers direct-to-consumer mobile testing services within the Moscow region.
News
Pangram dreams of a slop-free future.
Max Spero-a cofounder of Pangram, an AI detection tool popular among journalists-asks,
Read more
Report
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediate...
Read more
Report
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Detailed price information for KKR & Company LP (KKR-N) from The Globe and Mail including charting and trades.
Read more
Report
Max Spero (@max_spero_) on X
This is an important event: the first time AI-induced psychosis has affected a well-respected and high achieving individual. In this case, ChatGPT started spitting out SCP-style roleplay, and it seems like memory is playing a large part in ensuring the ha
Read more
Report
Pro access
Upgrade to see all 13 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.